AI-native platform designing RNA molecules ("biological software") with deep learning
Inceptive is a Palo Alto AI-native biotech founded in 2021 by Jakob Uszkoreit, a co-inventor of the Transformer architecture and former Google Brain researcher. It uses deep learning to design novel RNA molecules — what it calls "biological software" — spanning mRNA, siRNA, ASOs and peptides, and partners with drugmakers to customize molecule-design models. It raised a ~$100M round in September 2023 led by Andreessen Horowitz and NVIDIA NVentures, and in 2026 signed a strategic AI collaboration with Alnylam Pharmaceuticals valued at up to ~$2B.
Biotech📍 Palo Alto, CAFounded 2021
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Inceptive going public?
No. Inceptive is private and has not filed to go public. There is no S-1 on file.
What is Inceptive's valuation in 2026?
No confirmed valuation is on record for Inceptive. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Inceptive filed an S-1?
No public S-1 is on file for Inceptive.
Who are Inceptive's investors?
Inceptive's investors include Andreessen Horowitz, NVIDIA NVentures.
How much has Inceptive raised?
Inceptive has raised $100M in total across 2 disclosed rounds, most recently a Series A of $100M in Sep 2023.
Is Inceptive publicly traded — can you buy Inceptive stock?
No. Inceptive is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Inceptive on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Jakob Uszkoreit
Founded
2021
HQ
Palo Alto, CA
Total Raised
$100M
Growth
Platform/partnership stage; monetizing via large pharma collaborations
Last Round
Series A — $100M (Sep 2023) · Lead: Andreessen Horowitz / NVIDIA NVentures
IPO Status
private
Fundraising Status
Series A · $100M · 3y ago
privateTotal raised $100M2 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series A
$100M
Sep 2023
Andreessen Horowitz / NVIDIA NVentures
—
Seed
—
Jan 2021
Andreessen Horowitz
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Inceptive — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
10
via greenhouse
Product-build share
50%
engineering, research, product, design
Trajectory
steady
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Computational design of biological experiments for model developmentData selection and quality evaluation for biological foundation modelsHigh-throughput data generation to advance ML designLeading Data-Driven Lab for AI MedicinesSecure Data Infrastructure for AIAccelerating impact through partnerships
Counted from Inceptive's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Jakob Uszkoreit
Investors
Andreessen Horowitz · NVIDIA NVentures
Products
AI "biological software" platform for RNA design
mRNA / siRNA / ASO / peptide sequence design
In-vivo cell-therapy applications
Competitors
Atomic AI · Therna Biosciences · Moderna · Generate Biomedicines
BiotechRNA TherapeuticsGenerative AITechBioAI Drug Discovery
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.